Subtype
Neuroendocrine Carcinoma
CI-CAN-00001275NECExplore in graph →
515 active trials12 approved drugs28 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001275NECExplore in graph →
Clinical trials
1,534 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (213)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02297087 | Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for Treatment | terminated | N/A | 12 | Western Regional Medical CenterOTHER | 1 | Nov 9, 2017 | clinicaltrials |
| NCT00374140 | Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer | completed | Phase 2 | 40 | Ahmad TarhiniOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues(PHRC-Merkel) |
| completed |
| Phase 2 |
| 35 |
| University Hospital, GrenobleOTHER |
| 1 |
| Oct 18, 2017 |
| clinicaltrials |
| NCT00003496 | Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer | terminated | Phase 2 | 4 | Burzynski Research InstituteOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT03279614 | Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma | unknown | Phase 2 | 45 | Peking UniversityOTHER | 1 | Sep 12, 2017 | clinicaltrials |
| NCT02876081 | Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex(THEN) | withdrawn | Phase 2 | 0 | Fondation Hôpital Saint-JosephOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT02995187 | Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC) | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT01987232 | Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer | completed | Phase 1 / Phase 2 | 32 | AmgenINDUSTRY | 3 | Aug 28, 2017 | clinicaltrials |
| NCT00717938 | A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer(RASTEN) | completed | Phase 3 | 390 | Lund University HospitalOTHER | 1 | Aug 25, 2017 | clinicaltrials |
| NCT01441297 | BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer | completed | Phase 2 | 24 | Ji-youn HanOTHER_GOV | 1 | Aug 25, 2017 | clinicaltrials |
| NCT00460356 | Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes | completed | — | 159 | Gynecologic Oncology GroupNETWORK | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00828139 | S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 189 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2017 | clinicaltrials |
| NCT02715102 | Circulating Tumor DNA in Patients at High Risk for Lung Cancer | terminated | — | 39 | Pathway GenomicsINDUSTRY | 1 | Aug 21, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT02425072 | NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | John VillanoOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT03244904 | Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment | unknown | — | 80 | Fujian Cancer HospitalOTHER_GOV | 0 | Aug 10, 2017 | clinicaltrials |
| NCT03219762 | Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC(Nabster) | unknown | Phase 2 | 65 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Jul 26, 2017 | clinicaltrials |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 0 | Jul 19, 2017 | clinicaltrials |
| NCT01575782 | Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer(Chloroquine) | terminated | Phase 1 | 5 | Maastricht Radiation OncologyOTHER | 1 | Jul 18, 2017 | clinicaltrials |
| NCT00856830 | Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | University of Alabama at BirminghamOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT00454324 | Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer(NRR) | terminated | Phase 2 | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT00958022 | Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer | terminated | Phase 1 | 7 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00129974 | Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer | terminated | Phase 2 | 1 | Tufts Medical CenterOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT01927887 | Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study | completed | N/A | 12 | Massachusetts General HospitalOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT03168607 | Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma | unknown | Phase 2 | 45 | Peking UniversityOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00043862 | The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)((SCLC)) | completed | Phase 2 | 60 | GlaxoSmithKlineINDUSTRY | 1 | May 31, 2017 | clinicaltrials |
| NCT00046111 | A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors | completed | Phase 1 | 1 | GlaxoSmithKlineINDUSTRY | 2 | May 30, 2017 | clinicaltrials |
| NCT01166191 | Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC) | completed | Phase 2 | 60 | Maastricht Radiation OncologyOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01539655 | Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib(Vandetanib) | completed | Phase 1 | 34 | SanofiINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT02109250 | CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice(CaprelsaReg) | completed | — | 10 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT00519896 | Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT01758458 | Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma | terminated | Phase 1 / Phase 2 | 4 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT01719861 | Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors | terminated | Phase 2 | 6 | Joel NealOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT02577627 | Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC | unknown | — | 5,000 | Optimata Ltd.INDUSTRY | 1 | Apr 4, 2017 | clinicaltrials |
| NCT00883181 | A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy | completed | — | 1,370 | AmgenINDUSTRY | 0 | Mar 15, 2017 | clinicaltrials |
| NCT00320359 | Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer | completed | Phase 3 | 700 | GlaxoSmithKlineINDUSTRY | 2 | Mar 1, 2017 | clinicaltrials |
| NCT00118248 | Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00093782 | Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01640847 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases | withdrawn | Phase 2 | 0 | ImunonINDUSTRY | 0 | Feb 7, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT03029858 | PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC Patients(ATHENE) | unknown | — | 155 | Guangdong Association of Clinical TrialsOTHER | 1 | Jan 24, 2017 | clinicaltrials |
| NCT01173458 | Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC) | completed | — | 25 | University of Kansas Medical CenterOTHER | 1 | Jan 10, 2017 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT02348450 | Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer | unknown | Phase 4 | 308 | Guangdong Association of Clinical TrialsOTHER | 1 | Dec 5, 2016 | clinicaltrials |
| NCT02980809 | Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer | unknown | Phase 2 | 60 | First Hospitals affiliated to the China PLA General HospitalOTHER_GOV | 0 | Dec 2, 2016 | clinicaltrials |
| NCT02972320 | Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic | unknown | Phase 2 | 60 | Yunpeng LiuOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02970786 | Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans | unknown | Phase 1 | 10 | Rigshospitalet, DenmarkOTHER | 1 | Nov 22, 2016 | clinicaltrials |
| NCT02755675 | uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung | unknown | Phase 2 | 120 | Rigshospitalet, DenmarkOTHER | 1 | Nov 21, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Nov 9, 2017source: clinicaltrials